Optoacoustic sensors for early disease detection and monitoring

Diabetes and cardiovascular disease (CVD) are responsible for the majority of the morbidity and mortality in the EU.

However, to date there is no technology available that offers a non-invasive and portable way for disseminated measurements of disease effects on the systemic level or for monitoring disease progression from early development stages.

RSENSE4Health aims to accelerate the exploitation of a powerful, portable optoacoustic sensor, developed under the FET Open project RSENSE.

For the first time, this sensor can non-invasively detect the systemic effects of diabetes and CVD developing in home environments – a performance not available to any other sensors. With more than one billion potential users, this technology has an enormous market and global impact potential.

To bring this innovation to the market, RSENSE4Health will sharpen product specifications with stakeholder interviews, solidify patent strategy, and identify an optimal regulatory and business roadmap.

RSENSE4Health will synergize with the RSENSE consortium to strengthen the exploitation plan and accelerate company spin-off and product launch.